The role of molecular tumor boards in neuro-oncology: a nationwide survey

被引：4

作者：

Hoenikl, Lisa S. ^{[1
,2
]}

Lange, Sebastian ^{[2
,3
]}

Butenschoen, Vicki M. ^{[1
]}

Delbridge, Claire ^{[2
,4
]}

Meyer, Bernhard ^{[1
]}

Combs, Stephanie E. ^{[5
]}

Illert, Anna Lena ^{[2
,6
]}

Schmidt-Graf, Friederike ^{[2
,7
]}

机构：

[1] Tech Univ Munich TUM, Dept Neurosurg, Klinikum Rechts Isar, Ismaninger Str 22, D-81675 Munich, Germany

[2] Tech Universitiy Munich TUM, Ctr Personalized Med ZPM, Klinikum Rechts Isar, Munich, Germany

[3] Tech Univ Munich TUM, Dept Med 2, Klinikum Rechts Isar, Munich, Germany

[4] Tech Univ Munich TUM, Inst Pathol, Dept Neuropathol, Munich, Germany

[5] Tech Univ Munich TUM, Dept Radiat Oncol, Klinikum Rechts Isar, Munich, Germany

[6] Tech Univ Munich TUM, Fac Med, Dept Med 3, Klinikum Rechts Isar, Munich, Germany

[7] Tech Univ Munich TUM, Dept Neurol, Klinikum Rechts Isar, Munich, Germany

来源：

BMC CANCER | 2024年 / 24卷 / 01期

关键词：

Neuro-oncology; Molecular tumor board; MTB; Target therapy; Personalized medicine; Precision oncology;

D O I：

10.1186/s12885-024-11858-x

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

BackgroundIn neuro-oncology, the inclusion of tumor patients in the molecular tumor board has only become increasingly widespread in recent years, but so far there are no standards for indication, procedure, evaluation, therapy recommendations and therapy implementation of neuro-oncological patients. The present work examines the current handling of neuro-oncological patients included in molecular tumor boards in Germany.MethodsWe created an online based survey with questions covering the handling of neuro-oncologic patient inclusion, annotation of genetic analyses, management of target therapies and the general role of molecular tumor boards in neuro-oncology in Germany. We contacted all members of the Neuro-Oncology working group (NOA) of the German Cancer Society (DKG) by e-mail.Results38 responses were collected. The majority of those who responded were specialists in neurosurgery or neurology with more than 10 years of professional experience working at a university hospital. Molecular tumor boards (MTB) regularly take place once a week and all treatment disciplines of neuro-oncology patients take part. The inclusions to the MTB are according to distinct tumors and predominantly in case of tumor recurrence. An independently MTB member mostly create the recommendations, which are regularly implemented in the tumor treatment. Recommendations are given for alteration classes 4 and 5. Problems exist mostly within the cost takeover of experimental therapies. The experimental therapies are mostly given in the department of medical oncology.ConclusionsMolecular tumor boards for neuro-oncological patients, by now, are not standardized in Germany. Similarities exists for patient inclusion and interpretation of molecular alterations; the time point of inclusion and implementation during the patient treatment differ between the various hospitals. Further studies for standardization and harmonisation are needed. In summary, most of the interviewees envision great opportunities and possibilities for molecular-based neuro-oncological therapy in the future.

引用

页数：9

共 16 条

[1] EANO guideline on rational molecular testing of gliomas, glioneuronal, and neuronal tumors in adults for targeted therapy selection [J].

Capper, David ;

Reifenberger, Guido ;

French, Pim J. ;

Schweizer, Leonille ;

Weller, Michael ;

Touat, Mehdi ;

Niclou, Simone P. ;

Euskirchen, Philipp ;

Haberler, Christine ;

Hegi, Monika E. ;

Brandner, Sebastian ;

Le Rhun, Emilie ;

Ruda, Roberta ;

Sanson, Marc ;

Tabatabai, Ghazaleh ;

Sahm, Felix ;

Wen, Patrick Y. ;

Wesseling, Pieter ;

Preusser, Matthias ;

van den Bent, Martin J. .

NEURO-ONCOLOGY, 2023, 25 (05) :813-826

[2] The High "Cost" of Experimental Drugs Obtained Through Health Litigation in Brazil [J].

da Silva, Ricardo Eccard ;

Lima, Elisangela da Costa ;

Novaes, Maria Rita C. G. ;

Osorio-de-Castro, Claudia G. S. .

FRONTIERS IN PHARMACOLOGY, 2020, 11

[3] Patient attrition in Molecular Tumour Boards: a systematic review [J].

Frost, Hannah ;

Graham, Donna M. ;

Carter, Louise ;

O'Regan, Paul ;

Landers, Donal ;

Freitas, Andre .

BRITISH JOURNAL OF CANCER, 2022, 127 (08) :1557-1564

[4] Lessons learned: the first consecutive 1000 patients of the CCCMunichLMU Molecular Tumor Board [J].

Heinrich, Kathrin ;

Miller-Phillips, Lisa ;

Ziemann, Frank ;

Hasselmann, Korbinian ;

Ruehlmann, Katharina ;

Flach, Madeleine ;

Biro, Dorottya ;

von Bergwelt-Baildon, Michael ;

Holch, Julian ;

Herold, Tobias ;

von Baumgarten, Louisa ;

Greif, Philip A. ;

Jeremias, Irmela ;

Wuerstlein, Rachel ;

Casuscelli, Jozefina ;

Spitzweg, Christine ;

Seidensticker, Max ;

Renz, Bernhard ;

Corradini, Stefanie ;

Baumeister, Philipp ;

Goni, Elisabetta ;

Tufman, Amanda ;

Jung, Andreas ;

Kumbrink, Joerg ;

Kirchner, Thomas ;

Klauschen, Frederick ;

Metzeler, Klaus H. ;

Heinemann, Volker ;

Westphalen, C. Benedikt .

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (05) :1905-1915

[5] Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with Rare Cancers [J].

Horak, Peter ;

Heining, Christoph ;

Kreutzfeldt, Simon ;

Hutter, Barbara ;

Mock, Andreas ;

Huellein, Jennifer ;

Froehlich, Martina ;

Uhrig, Sebastian ;

Jahn, Arne ;

Rump, Andreas ;

Gieldon, Laura ;

Moehrmann, Lino ;

Hanf, Dorothea ;

Teleanu, Veronica ;

Heilig, Christoph E. ;

Lipka, Daniel B. ;

Allgaeuer, Michael ;

Ruhnke, Leo ;

Lassmann, Andreas ;

Endris, Volker ;

Neumann, Olaf ;

Penzel, Roland ;

Beck, Katja ;

Richter, Daniela ;

Winter, Ulrike ;

Wolf, Stephan ;

Pfuetze, Katrin ;

Geoerg, Christina ;

Meissburger, Bettina ;

Buchhalter, Ivo ;

Augustin, Marinela ;

Aulitzky, Walter E. ;

Hohenberger, Peter ;

Kroiss, Matthias ;

Schirmacher, Peter ;

Schlenk, Richard F. ;

Keilholz, Ulrich ;

Klauschen, Frederick ;

Folprecht, Gunnar ;

Bauer, Sebastian ;

Siveke, Jens Thomas ;

Brandts, Christian H. ;

Kindler, Thomas ;

Boerries, Melanie ;

Illert, Anna L. ;

von Bubnoff, Nikolas ;

Jost, Philipp J. ;

Spiekermann, Karsten ;

Bitzer, Michael ;

Schulze-Osthoff, Klaus .

CANCER DISCOVERY, 2021, 11 (11) :2780-2795

[6] The German Network for Personalized Medicine to enhance patient care and translational research [J].

Illert, A. L. ;

Stenzinger, A. ;

Bitzer, M. ;

Horak, P. ;

Gaidzik, V. I. ;

Moeller, Y. ;

Beha, J. ;

Oener, Oe ;

Schmitt, F. ;

Lassmann, S. ;

Ossowski, S. ;

Schaaf, C. P. ;

Hallek, M. ;

Bruemmendorf, T. H. ;

Albers, P. ;

Fehm, T. ;

Brossart, P. ;

Glimm, H. ;

Schadendorf, D. ;

Bleckmann, A. ;

Brandts, C. H. ;

Esposito, I ;

Mack, E. ;

Peters, C. ;

Bokemeyer, C. ;

Froehling, S. ;

Kindler, T. ;

Alguel, H. ;

Heinemann, V ;

Doehner, H. ;

Bargou, R. ;

Ellenrieder, V. ;

Hillemanns, P. ;

Lordick, F. ;

Hochhaus, A. ;

Beckmann, M. W. ;

Pukrop, T. ;

Trepel, M. ;

Sundmacher, L. ;

Wesselmann, S. ;

Nettekoven, G. ;

Kohlhuber, F. ;

Heinze, O. ;

Budczies, J. ;

Werner, M. ;

Nikolaou, K. ;

Beer, A. J. ;

Tabatabai, G. ;

Weichert, W. ;

Keilholz, U. .

NATURE MEDICINE, 2023, 29 (06) :1298-1301

[7] Comprehensive cancer predisposition testing within the prospective MASTER trial identifies hereditary cancer patients and supports treatment decisions for rare cancers [J].

Jahn, A. ;

Rump, A. ;

Widmann, T. J. ;

Heining, C. ;

Horak, P. ;

Hutter, B. ;

Paramasivam, N. ;

Uhrig, S. ;

Gieldon, L. ;

Drukewitz, S. ;

Kuebler, A. ;

Bermudez, M. ;

Hackmann, K. ;

Porrmann, J. ;

Wagner, J. ;

Arlt, M. ;

Franke, M. ;

Fischer, J. ;

Kowalzyk, Z. ;

William, D. ;

Weth, V. ;

Oster, S. ;

Froehlich, M. ;

Huellein, J. ;

Gonzalez, C. Valle ;

Kreutzfeldt, S. ;

Mock, A. ;

Heilig, C. E. ;

Lipka, D. B. ;

Moehrmann, L. ;

Hanf, D. ;

Oles, M. ;

Teleanu, V. ;

Allgaeuer, M. ;

Ruhnke, L. ;

Kutz, O. ;

Knurr, A. ;

Lassmann, A. ;

Endris, V. ;

Neumann, O. ;

Penzel, R. ;

Beck, K. ;

Richter, D. ;

Winter, U. ;

Wolf, S. ;

Pfuetze, K. ;

Geoerg, C. ;

Meissburger, B. ;

Buchhalter, I. ;

Augustin, M. .

ANNALS OF ONCOLOGY, 2022, 33 (11) :1186-1199

[8] Molecular testing for adolescent and young adult central nervous system tumors: A Canadian guideline [J].

Lim-Fat, Mary Jane ;

Macdonald, Maria ;

Lapointe, Sarah ;

Climans, Seth Andrew ;

Cacciotti, Chantel ;

Chahal, Manik ;

Perreault, Sebastien ;

Tsang, Derek S. ;

Gao, Andrew ;

Yip, Stephen ;

Keith, Julia ;

Bennett, Julie ;

Ramaswamy, Vijay ;

Detsky, Jay ;

Tabori, Uri ;

Das, Sunit ;

Hawkins, Cynthia .

FRONTIERS IN ONCOLOGY, 2022, 12

[9] The 2021 WHO Classification of Tumors of the Central Nervous System: a summary [J].

Louis, David N. ;

Perry, Arie ;

Wesseling, Pieter ;

Brat, Daniel J. ;

Cree, Ian A. ;

Figarella-Branger, Dominique ;

Hawkins, Cynthia ;

Ng, H. K. ;

Pfister, Stefan M. ;

Reifenberger, Guido ;

Soffietti, Riccardo ;

von Deimling, Andreas ;

Ellison, David W. .

NEURO-ONCOLOGY, 2021, 23 (08) :1231-1251

[10] Molecular Tumor Boarcs in Clinical Prac ice [J].

Luchini, Claudio ;

Lawlor, Rita T. ;

Milella, Michele ;

Scarpa, Aldo .

TRENDS IN CANCER, 2020, 6 (09) :738-744

← 1 2 →